Scandion Oncology has a unique aim: to develop drugs that specifically target molecular drug resistance mechanisms in cancer cells. Our mission is to improve the outcome and quality of life for cancer patients with chemotherapy-resistant disease.
Many cancer patients initially benefit from chemotherapy treatment, but a large proportion will develop resistance against the chemotherapy used. Few of these patients survive.
Our ambition is to bring our lead compound SCO-101, which has already successfully passed 4 Phase I studies, through clinical proof-of-concept Phase II studies conducted on chemotherapy-resistant metastatic colorectal cancer and metastatic breast cancer patients. Our other potential anti-cancer drug, SCO-201, will be taken through pre-clinical and clinical validation studies.
For both products, we will seek partnership with big pharma to obtain FDA and EMEA approval followed by an introduction to the market.